Literature DB >> 20497197

UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Girolamo Calo'1, Anna Rizzi, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura, Domenico Regoli, Maurizio Massi, Severo Salvadori, David G Lambert, Remo Guerrini.   

Abstract

Nociceptin/orphanin FQ (N/OFQ) controls several biological functions via selective activation of the N/OFQ peptide receptor (NOP). [(pF)Phe(4) Aib(7) Arg(14) Lys(15) ]N/OFQ-NH(2) (UFP-112) is an NOP receptor ligand designed using a combination of several chemical modifications in the same peptide sequence that increase NOP receptor affinity/potency and/or reduce susceptibility to enzymatic degradation. In the present review article, we summarize data from the literature and present original findings on the in vitro and in vivo pharmacological features of UFP-112. Moreover, important biological actions and possible therapeutic indications of NOP receptor agonists are discussed based on the results obtained with UFP-112 and compared with other peptide and nonpeptide NOP receptor ligands.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20497197      PMCID： PMC6493780          DOI： 10.1111/j.1755-5949.2009.00107.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN： 1755-5930            Impact factor:   5.243


  156 in total

1.  Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library.

Authors:  J A Becker; A Wallace; A Garzon; P Ingallinella; E Bianchi; R Cortese; F Simonin; B L Kieffer; A Pessi
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

2.  Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.

Authors:  K Varani; A Rizzi; G Calo; R Bigoni; G Toth; R Guerrini; S Gessi; S Salvadori; P A Borea; D Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-09       Impact factor: 3.000

3.  Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus.

Authors:  A Rizzi; G Calò; M Trevisani; M Tognetto; L Fabbri; C Mapp; R Guerrini; S Salvadori; D Regoli; P Geppetti
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

4.  In vivo metabolism of nociceptin/orphanin FQ in rat hippocampus.

Authors:  J Sandin; J Georgieva; J Silberring; L Terenius
Journal:  Neuroreport       Date:  1999-01-18       Impact factor: 1.837

5.  Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors.

Authors:  H Okawa; B Nicol; R Bigoni; R A Hirst; G Calo; R Guerrini; D J Rowbotham; D Smart; A T McKnight; D G Lambert
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Cardiovascular effects of nociceptin in unanesthetized mice.

Authors:  P Madeddu; M B Salis; A F Milia; C Emanueli; R Guerrini; D Regoli; G Calò
Journal:  Hypertension       Date:  1999-03       Impact factor: 10.190

7.  8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists.

Authors:  J Wichmann; G Adam; S Röver; A M Cesura; F M Dautzenberg; F Jenck
Journal:  Bioorg Med Chem Lett       Date:  1999-08-16       Impact factor: 2.823

8.  Orphanin FQ/nociceptin blocks acquisition of morphine place preference.

Authors:  N P Murphy; Y Lee; N T Maidment
Journal:  Brain Res       Date:  1999-06-19       Impact factor: 3.252

9.  Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice.

Authors:  A Köster; A Montkowski; S Schulz; E M Stübe; K Knaudt; F Jenck; J L Moreau; H P Nothacker; O Civelli; R K Reinscheid
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

10.  Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.

Authors:  R Bigoni; S Giuliani; G Calo'; A Rizzi; R Guerrini; S Salvadori; D Regoli; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-03       Impact factor: 3.000
View more
  9 in total

Review 1.  Central N/OFQ-NOP Receptor System in Pain Modulation.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  Adv Pharmacol       Date:  2015-12-17

Review 2.  Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.

Authors:  Norikazu Kiguchi; Huiping Ding; Shiroh Kishioka; Mei-Chuan Ko
Journal:  Curr Top Med Chem       Date:  2020       Impact factor: 3.295

3.  In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.

Authors:  A Rizzi; D Malfacini; M C Cerlesi; C Ruzza; E Marzola; M F Bird; D J Rowbotham; S Salvadori; R Guerrini; D G Lambert; G Calo
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 4.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

Review 5.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

6.  Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.

Authors:  G Calo; D G Lambert
Journal:  Br J Anaesth       Date:  2018-08-22       Impact factor: 9.166

Review 7.  Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  J Neurosci Res       Date:  2020-04-07       Impact factor: 4.433

Review 8.  Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.

Authors:  Massimo Ubaldi; Nazzareno Cannella; Anna Maria Borruto; Michele Petrella; Maria Vittoria Micioni Di Bonaventura; Laura Soverchia; Serena Stopponi; Friedbert Weiss; Carlo Cifani; Roberto Ciccocioppo
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 6.208

Review 9.  Underlying Susceptibility to Eating Disorders and Drug Abuse: Genetic and Pharmacological Aspects of Dopamine D4 Receptors.

Authors:  Luca Botticelli; Emanuela Micioni Di Bonaventura; Fabio Del Bello; Gianfabio Giorgioni; Alessandro Piergentili; Adele Romano; Wilma Quaglia; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura
Journal:  Nutrients       Date:  2020-07-30       Impact factor: 5.717
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.